These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33111497)

  • 1. Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience.
    Lavie M; Diamant N; Cahal M; Sadot E; Be'er M; Fattal-Valevski A; Sagi L; Domany KA; Amirav I
    Pediatr Pulmonol; 2021 Jan; 56(1):291-298. PubMed ID: 33111497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 3. Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen.
    Xiao L; Chiang J; Castro-Codesal M; Kolski H; Bedi P; Al Amrani F; Gonorazky HD; Amin R;
    Pediatr Pulmonol; 2023 Jan; 58(1):161-170. PubMed ID: 36193036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients.
    Lavie M; Rochman M; Sagi L; Yerushalmy Feler A; Ovadia D; Cahal M; Be'er M; Sadot E; Fattal-Valevski A; Amirav I
    Pediatr Pulmonol; 2022 Mar; 57(3):686-694. PubMed ID: 34921596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen.
    Ergenekon AP; Yilmaz Yegit C; Cenk M; Gokdemir Y; Erdem Eralp E; Ozturk G; Unver O; Kenis Coskun O; Karadag Saygi E; Turkdogan D; Karadag B
    Pediatr Int; 2022 Jan; 64(1):e15175. PubMed ID: 35522792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen.
    Sansone VA; Pirola A; Albamonte E; Pane M; Lizio A; D'Amico A; Catteruccia M; Cutrera R; Bruno C; Pedemonte M; Messina S; Rao F; Roma E; Salmin F; Coratti G; Di Bari A; De Sanctis R; Pera CM; Sframeli M; Piastra M; Macagno F; Vita G; Bertini E; Mercuri E
    J Pediatr; 2020 Apr; 219():223-228.e4. PubMed ID: 32035635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen.
    de Holanda Mendonça R; Jorge Polido G; Ciro M; Jorge Fontoura Solla D; Conti Reed U; Zanoteli E
    J Neuromuscul Dis; 2021; 8(2):217-224. PubMed ID: 33459657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
    Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
    Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Symptomatic Spinal Muscular Atrophy with Nusinersen: A Prospective Longitudinal Study on Scoliosis Progression.
    Ip HNH; Yu MKL; Wong WHS; Liu A; Kwan KYH; Chan SHS
    J Neuromuscul Dis; 2024; 11(2):349-359. PubMed ID: 38363614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study.
    Aragon-Gawinska K; Seferian AM; Daron A; Gargaun E; Vuillerot C; Cances C; Ropars J; Chouchane M; Cuppen I; Hughes I; Illingworth M; Marini-Bettolo C; Rambaud J; Taytard J; Annoussamy M; Scoto M; Gidaro T; Servais L
    Neurology; 2018 Oct; 91(14):e1312-e1318. PubMed ID: 30158155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1.
    Fitzgerald DA; Doumit M; Abel F
    Paediatr Respir Rev; 2018 Sep; 28():11-17. PubMed ID: 30414815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
    Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
    N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs.
    Edel L; Grime C; Robinson V; Manzur A; Abel F; Munot P; Ridout D; Scoto M; Muntoni F; Chan E
    Neuromuscul Disord; 2021 Apr; 31(4):300-309. PubMed ID: 33752934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen.
    Menard J; Seferian AM; Fleurence E; Barzic A; Binoche A; Labouret G; Coutier L; Vuillerot C; Bieleu BM; Gomez Garcia de la Banda M; Corvol H; Servais L; Taytard J
    Pediatr Pulmonol; 2022 Jun; 57(6):1505-1512. PubMed ID: 35307979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results.
    Jiang Y; Wang Y; Xiong H; Li W; Luo R; Chen W; Yin F; Lü J; Liang J; Chen WJ; Lu X; Wang H; Tang J; Monine M; Makepeace C; Jin X; Foster R; Chin R; Berger Z
    Adv Ther; 2024 Jul; 41(7):2743-2756. PubMed ID: 38722537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
    Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
    Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
    [No Abstract]   [Full Text] [Related]  

  • 19. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen.
    Weststrate H; Stimpson G; Thomas L; Scoto M; Johnson E; Stewart A; Muntoni F; Baranello G; Conway E;
    Dev Med Child Neurol; 2022 Jul; 64(7):907-914. PubMed ID: 35103306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment.
    Desguerre I; Barrois R; Audic F; Barnerias C; Chabrol B; Davion JB; Durigneux J; Espil-Taris C; Gomez-Garcia de la Banda M; Guichard M; Isapof A; Nougues MC; Laugel V; Le Goff L; Mercier S; Pervillé A; Richelme C; Thibaud M; Sarret C; Schweitzer C; Testard H; Trommsdorff V; Vanhulle C; Walther-Louvier U; Altuzarra C; Chouchane M; Ropars J; Quijano-Roy S; Cances C
    Orphanet J Rare Dis; 2024 Sep; 19(1):344. PubMed ID: 39272200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.